东方生物(688298) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 reached ¥1,018,718,816.72, representing a year-on-year increase of 273.82%[7] - The net profit attributable to shareholders for Q3 2021 was ¥525,017,889.42, with a year-on-year growth of 273.65%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥525,658,191.94, reflecting an increase of 288.50% year-on-year[7] - Total operating revenue for the first three quarters of 2021 reached CNY 7,400,700,987.86, a significant increase from CNY 1,100,668,333.11 in the same period of 2020, representing a growth of approximately 573%[35] - Net profit attributable to shareholders of the parent company for the third quarter was CNY 3,919,267,583.04, compared to CNY 664,456,764.88 in the previous year, marking an increase of about 489%[38] - The company reported a net profit of CNY 4,610,206,289.31 for the third quarter, compared to CNY 773,228,902.33 in the previous year, marking an increase of approximately 496%[38] Assets and Equity - The total assets as of the end of Q3 2021 amounted to ¥7,263,988,174.30, a 103.29% increase compared to the end of the previous year[11] - The equity attributable to shareholders at the end of Q3 2021 was ¥5,862,354,740.61, showing a 139.67% increase from the previous year[11] - The total equity attributable to shareholders of the parent company reached CNY 5,862,354,740.61, compared to CNY 2,446,042,711.91 in the previous year, representing a growth of approximately 140%[35] - The company's total assets amounted to CNY 7,263,988,174.30, up from CNY 3,573,223,438.30, indicating an increase of about 103%[35] Earnings Per Share - The basic earnings per share for Q3 2021 was ¥4.38, up 274.36% year-on-year[11] - The diluted earnings per share for Q3 2021 was also ¥4.38, reflecting a similar growth rate of 274.36%[11] - The basic earnings per share for the third quarter was CNY 32.66, compared to CNY 5.54 in the same period last year, reflecting an increase of approximately 487%[40] Research and Development - Research and development expenses for Q3 2021 totaled ¥47,341,068.76, an increase of 221.82% compared to the same period last year[11] - Research and development expenses for the first three quarters amounted to CNY 243,025,375.01, up from CNY 41,411,748.41 in the previous year, indicating an increase of about 485%[36] - The R&D expenses accounted for 4.65% of operating revenue in Q3 2021, a decrease of 0.75 percentage points year-on-year[11] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥4,197,448,196.49, reflecting a significant increase of 685.18%[11] - Operating cash inflow for the first three quarters of 2021 reached ¥7,680,019,835.27, a significant increase from ¥1,040,317,918.31 in the same period of 2020, representing a growth of approximately 639%[45] - The net cash flow from operating activities for the first three quarters of 2021 was ¥4,197,448,196.49, compared to ¥534,585,400.26 in 2020, indicating a substantial increase of about 684%[45] - Cash inflow from investment activities totaled ¥1,226,140,847.78 in 2021, down from ¥2,221,517,656.22 in 2020, reflecting a decrease of approximately 45%[46] - The net cash flow from investment activities was -¥690,076,969.20 in 2021, compared to -¥563,551,065.09 in 2020, indicating a worsening of cash flow by about 22.5%[46] - The total cash and cash equivalents at the end of the period in 2021 stood at ¥5,291,584,604.49, compared to ¥558,611,426.16 at the end of 2020, showing an increase of approximately 846%[46] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,688[19] - The largest shareholder, Anji Fulanglai Import and Export Trading Co., Ltd., holds 23,400,000 shares, accounting for 19.50% of the total shares[19] - The second largest shareholder, Fangs Holdings Limited Liability Company, holds 22,500,000 shares, representing 18.75% of the total shares[19] - The company has a total of 48.56% of shares held by the three largest shareholders, indicating a concentrated ownership structure[25] - The company has engaged in margin trading, with specific shareholders participating in this activity, indicating active trading strategies[25] Liabilities - The total liabilities increased to CNY 1,388,603,618.18 from CNY 1,121,810,035.03, reflecting a growth of approximately 24%[35]